Post Profile

PharmaMar announces positive results from its Phase 2 study with PM1183 in BRCA 1/2 MBC

(Pharmamar) The data was presented at an oral session at the European Society of Medical Oncology.The study meets its primary objective obtaining an overall response rate (ORR) in 41 percent of the patients. In the BRCA 2 subgroup, the ORR was 61 percent, while in those patients with BRCA 1, this was 26 percent.
read more


Related Posts

Positive Results From Phase 2 Clinical Study Of NKTR-102 In Metastatic Breast Cancer Presented In Oral Session At The ASCO 2011 Symposium

Health : Medical News Today

Nektar Therapeutics (Nasdaq: NKTR) announced that positive results from the company's Phase 2 clinical study of NKTR-102 in patients with metastatic breast cancer were presented at the ASCO 2011 Breast Cancer Symposium in San Franci...

New OPAXIO And Tosedostat Data Selected For Oral Discussion Sessions At The 2011 American Society Of Clinical Oncology (ASCO) Annual Meeting

Health : Medical News Today

Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced that data from a study with OPAXIO(TM) (paclitaxel poliglumex or PPX), in patients with newly diagnosed high-grade gliomas, and interim results from a study of tosedosta...

PharmaMar Announces The Initiation Of Phase I Clinical Trials With PM1183, A New Antitumor Compound

Health : Medical News Today

PharmaMar SA (Grupo Zeltia, ZEL.MC) announces the initiation of Phase I clinical trials with PM1183, a new antitumor compound developed by PharmaMar's internal research program. The first patient enrolled in the trial has already st...

PharmaMar completes the patient recruitment for the Phase 3 pivotal study with PM1183

Health : EurekAlert: Health

(Pharmamar) PharmaMar announces today that the patient recruitment for the randomized and pivotal Phase III 'CORAIL' study with lurbinectedin (PM1183), for the treatment of platinum-resistant ovarian cancer, has been successfully co...

Phase II Study Results - E7080 Has Objective Response Rate Of 59% In Radioiodine (RAI)-Refractory Differentiated Thyroid Cancer

Health : Medical News Today

Preliminary results of a Phase II study to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting showed that Eisai's E7080 (lenvatinib [USAN]) demonstrated an Objective Response Rate (ORR) of 59% (34/58, 95...


Copyright © 2016 Regator, LLC